Effect of EPA/DHA treatment on coronary hyperintense plaque detected by non-contrast T1-weighted magnetic resonance imaging
Latest Information Update: 30 Oct 2020
At a glance
- Drugs Omega-3-acid ethyl esters (Primary) ; HMG-CoA reductase inhibitors
- Indications Coronary artery disease; Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms AQUAMARINE EPA/DHA
- 30 Oct 2020 New trial record
- 01 Sep 2020 Results of subgroup analysis effect of EPA/DHA on coronary high-intensity plaques, presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology